Nasdaq · CIK 0001840229
INKT MiNK Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 41 d ago. Close $10.72 on Oct 9, 2026, +25% from the 52-week low and -28% from the high.
In brief
MiNK Therapeutics, Inc. (INKT) has 60 SEC Form 4 filings on file from 8 insiders, the latest filed on Sep 2, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
4 open-market trades have been scored at INKT. The newest: Barbara Ryan (director) sold $19k of stock on Jun 4, 2026, filed Jun 5, 2026, scored 15 (weak). The largest of the 4 shown: Agenus Inc (10% owner) bought $25k on Oct 12, 2023, scored 15 (weak).
1 Form 144 notice of planned sales is on file, the latest filed Aug 29, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at MiNK Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Barbara Ryan director sell | $19k 1,500 shares | -6% | +83% from low-80% from high | |
| 15Weak | Barbara Ryan director sell | $22k 1,500 shares | -7% | - | |
| 15Weak | Barbara Ryan director sell | $5,426 500 shares | -2% | - | |
| 15Weak | Agenus Inc owner buy | $25k 22,975 shares | +0% | +30% from low-66% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 29, 2025 | Agenus Inc. Owner | 786,750 19.84% of outstanding | $13M | Aug 29, 2025 | none |
Transactions
The newest 50 of 77 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Ulf Wiinberg director | AGrant or award Common Stock | +1,279 | $10.95 | $14k | 23,929 | 41 d ago |
| Sep 1, 2026 | Barbara Ryan director | AGrant or award Common Stock | +1,622 | $10.95 | $18k | 23,591 | 41 d ago |
| Sep 1, 2026 | Brian Corvese director | AGrant or award Common Stock | +1,633 | $10.95 | $18k | 54,770 | 41 d ago |
| Sep 1, 2026 | John Bradley Holcomb director | AGrant or award Common Stock | +1,233 | $10.95 | $14k | 4,691 | 41 d ago |
| Sep 1, 2026 | Peter Behner director | AGrant or award Common Stock | +1,485 | $10.95 | $16k | 24,404 | 41 d ago |
| Jun 4, 2026 | Barbara Ryan director | SOpen-market sale Common Stock | -500 | $12.68 | $6,342 | 22,969 | Jun 5, 2026 |
| Jun 4, 2026 | Barbara Ryan director | SOpen-market sale Common Stock | -1,000 | $12.80 | $13k | 21,969 | Jun 5, 2026 |
| Mar 2, 2026 | Brian Corvese director | AGrant or award Common Stock | +1,640 | $10.90 | $18k | 51,693 | Jun 2, 2026 |
| Mar 2, 2026 | Peter Behner director | AGrant or award Common Stock | +1,491 | $10.90 | $16k | 21,606 | Jun 2, 2026 |
| Mar 2, 2026 | Barbara Ryan director | AGrant or award Common Stock | +1,629 | $10.90 | $18k | 22,035 | Jun 2, 2026 |
| Mar 2, 2026 | Ulf Wiinberg director | AGrant or award Common Stock | +1,285 | $10.90 | $14k | 21,519 | Jun 2, 2026 |
| Mar 2, 2026 | John Bradley Holcomb director | AGrant or award Common Stock | +1,239 | $10.90 | $14k | 2,367 | Jun 2, 2026 |
| Jun 1, 2026 | Peter Behner director | AGrant or award Common Stock | +1,313 | $12.38 | $16k | 22,919 | Jun 2, 2026 |
| Jun 1, 2026 | Brian Corvese director | AGrant or award Common Stock | +1,444 | $12.38 | $18k | 53,137 | Jun 2, 2026 |
| Jun 1, 2026 | John Bradley Holcomb director | AGrant or award Common Stock | +1,091 | $12.38 | $14k | 3,458 | Jun 2, 2026 |
| Jun 1, 2026 | Ulf Wiinberg director | AGrant or award Common Stock | +1,131 | $12.38 | $14k | 22,650 | Jun 2, 2026 |
| Jun 1, 2026 | Barbara Ryan director | AGrant or award Common Stock | +1,434 | $12.38 | $18k | 23,469 | Jun 2, 2026 |
| Sep 23, 2025 | John Bradley Holcomb director | AGrant or award Stock Option (Right to Buy)derivative | +4,174 | $0.00 | $0 | 4,174 | Apr 30, 2026 |
| Mar 9, 2026 | Barbara Ryan director | SOpen-market sale Common Stock | -200 | $10.17 | $2,035 | 21,706 | Mar 11, 2026 |
| Mar 10, 2026 | Barbara Ryan director | SOpen-market sale Common Stock | -300 | $15.28 | $4,585 | 21,406 | Mar 11, 2026 |
| Mar 10, 2026 | Barbara Ryan director | SOpen-market sale Common Stock | -500 | $15.57 | $7,783 | 20,906 | Mar 11, 2026 |
| Mar 10, 2026 | Barbara Ryan director | SOpen-market sale Common Stock | -500 | $15.30 | $7,650 | 20,406 | Mar 11, 2026 |
| Feb 27, 2026 | Barbara Ryan director | SOpen-market sale Common Stock | -400 | $10.86 | $4,343 | 22,006 | Mar 4, 2026 |
| Mar 2, 2026 | Barbara Ryan director | SOpen-market sale Common Stock | -100 | $10.83 | $1,083 | 21,906 | Mar 4, 2026 |
| Jan 2, 2026 | Jennifer Buell Chief Executive Officer | FTax withholding Common Stock | -10,024 | $11.12 | $111k | 57,942 | Jan 14, 2026 |
| Jan 2, 2026 | Peter Behner director | AGrant or award Stock Option (Right to Buy)derivative | +5,395 | $0.00 | $0 | 5,395 | Jan 6, 2026 |
| Jan 2, 2026 | Jennifer Buell Chief Executive Officer | AGrant or award Common Stock | +31,474 | $11.12 | $350k | 67,966 | Jan 6, 2026 |
| Jan 2, 2026 | Brian Corvese director | AGrant or award Stock Option (Right to Buy)derivative | +5,395 | $0.00 | $0 | 5,395 | Jan 6, 2026 |
| Jan 2, 2026 | Barbara Ryan director | AGrant or award Stock Option (Right to Buy)derivative | +5,395 | $0.00 | $0 | 5,395 | Jan 6, 2026 |
| Jan 2, 2026 | Ulf Wiinberg director | AGrant or award Stock Option (Right to Buy)derivative | +5,395 | $0.00 | $0 | 5,395 | Jan 6, 2026 |
| Jan 2, 2026 | Jennifer Buell Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jan 6, 2026 |
| Dec 1, 2025 | Brian Corvese director | AGrant or award Common Stock | +1,612 | $11.09 | $18k | 50,053 | Dec 3, 2025 |
| Dec 1, 2025 | John Bradley Holcomb director | AGrant or award Common Stock | +1,128 | $11.09 | $13k | 1,128 | Dec 3, 2025 |
| Dec 1, 2025 | Robert Peter Kadlec director | AGrant or award Common Stock | +1,218 | $11.09 | $14k | 19,126 | Dec 3, 2025 |
| Dec 1, 2025 | Ulf Wiinberg director | AGrant or award Common Stock | +1,263 | $11.09 | $14k | 20,234 | Dec 3, 2025 |
| Dec 1, 2025 | Barbara Ryan director | AGrant or award Common Stock | +1,601 | $11.09 | $18k | 22,406 | Dec 3, 2025 |
| Dec 1, 2025 | Peter Behner director | AGrant or award Common Stock | +1,466 | $11.09 | $16k | 20,115 | Dec 3, 2025 |
| Sep 9, 2025 | Jennifer Buell Chief Executive Officer | FTax withholding Common Stock | -5,351 | $15.36 | $82k | 36,492 | Oct 3, 2025 |
| Sep 9, 2025 | Peter Behner director | AGrant or award Stock Option (Right to Buy)derivative | +3,225 | $0.00 | $0 | 3,225 | Sep 11, 2025 |
| Sep 9, 2025 | Jennifer Buell Chief Executive Officer | AGrant or award Common Stock | +18,229 | $15.36 | $280k | 41,913 | Sep 11, 2025 |
| Sep 9, 2025 | Brian Corvese director | AGrant or award Stock Option (Right to Buy)derivative | +3,225 | $0.00 | $0 | 3,225 | Sep 11, 2025 |
| Sep 9, 2025 | Robert Peter Kadlec director | AGrant or award Stock Option (Right to Buy)derivative | +3,225 | $0.00 | $0 | 3,225 | Sep 11, 2025 |
| Sep 9, 2025 | Barbara Ryan director | AGrant or award Stock Option (Right to Buy)derivative | +3,225 | $0.00 | $0 | 3,225 | Sep 11, 2025 |
| Sep 9, 2025 | Ulf Wiinberg director | AGrant or award Stock Option (Right to Buy)derivative | +3,225 | $0.00 | $0 | 3,225 | Sep 11, 2025 |
| Sep 9, 2025 | Jennifer Buell Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Sep 11, 2025 |
| Sep 2, 2025 | Peter Behner director | AGrant or award Common Stock | +1,173 | $13.86 | $16k | 18,649 | Sep 3, 2025 |
| Sep 2, 2025 | Brian Corvese director | AGrant or award Common Stock | +1,290 | $13.86 | $18k | 48,441 | Sep 3, 2025 |
| Sep 2, 2025 | Robert Peter Kadlec director | AGrant or award Common Stock | +975 | $13.86 | $14k | 17,908 | Sep 3, 2025 |
| Sep 2, 2025 | Barbara Ryan director | AGrant or award Common Stock | +1,281 | $13.86 | $18k | 20,805 | Sep 3, 2025 |
| Sep 2, 2025 | Ulf Wiinberg director | AGrant or award Common Stock | +1,011 | $13.86 | $14k | 18,971 | Sep 3, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Agenus Incowner
- Peter Behnerdirector
- Jennifer BuellChief Executive Officer
- Brian Corvesedirector
- John Bradley Holcombdirector
- Robert Peter Kadlecdirector
- Barbara Ryandirector
- Ulf Wiinbergdirector
Questions about INKT
Answered from the filings on this page, as of the latest one.
Are insiders buying INKT?
No. In the last 90 days no insider at MiNK Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade INKT on the open market?
Barbara Ryan (director) sold $19k of INKT on Jun 4, 2026 and filed the Form 4 on Jun 5, 2026. InsiderTell scored 15 (weak).
How many insiders file Form 4 at MiNK Therapeutics, Inc.?
8 people have filed a Form 4 at MiNK Therapeutics, Inc., among them Agenus Inc (10% owner), Peter Behner (director), Jennifer Buell (Chief Executive Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.